Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
2.6
Journals
Current Oncology
Special Issues
Future Perspectives for Diagnosis and Treatment of Acute Myeloid Leukemia...
share announcement

Future Perspectives for Diagnosis and Treatment of Acute Myeloid Leukemia (AML)

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 2952

Special Issue Editors

Prof. Dr. Vera Ulrike Bacher

E-Mail Website
Guest Editor
Department of Hematology, University Hospital Bern, 3010 Bern, Switzerland
Interests: hematologic diagnostics; flow cytometry; cytomorphology; molecular genetics; measurable disease diagnostics; acute leukemias; chronic leukemias; lymphomas; myeloma; personalized therapies; interaction of diagnostics and therapies in hematology; prognosis; predictive markers
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Thomas Pabst

E-Mail Website
Co-Guest Editor
Head of Project Group Leukemia of the Swiss Group for Clinical Cancer Research, SAKK & Head of the Section Hemato-Oncology at Bern University Hospital, Inselspital, Bern, Switzerland
Interests: hemato-oncologic diagnostics; myeloid malignancies; plasma cell disorders; leukemia and myeloma therapy; CAR-T cell therapy
Special Issues, Collections and Topics in MDPI journals
Dr. Georg Stüssi

E-Mail Website
Co-Guest Editor
Head of the Hematology Department of Ospedale Regionale di Bellinzona, Bellinzona, Switzerland
Interests: leukemia in the elderly; hematologic diagnostics; myeloproliferative neoplasms

Special Issue Information

Dear Colleagues,

Diagnostic and therapeutic options for patients with acute myeloid leukemia (AML) have been steadily increasing in recent years. The incorporation of next-generation sequencing (NGS) technologies in the diagnosis of AML allowed for improving risk stratification and therapeutic planning in AML patients. Furthermore, NGS was shown to be able to contribute as well monitor diagnostics during or after treatment, which is currently being explored in clinical studies. Targeted therapies are increasingly available, with IDH1 and IDH2 inhibitors, as well as with an expanding arsenal of FLT3 inhibitors. Vyxeos®, providing a fixed combination of daunorubicin and cytarabine, has been approved for intensive induction therapy of patients with therapy-associated AML, secondary AML following MDS, and de novo AML with MDS-related changes. Gemtuzumab Ozogamicin, a monoclonal CD33 antibody, may be added to intensive induction chemotherapy. For patients who cannot tolerate intensive induction, the combination of hypomethylating agents with venetoclax, a BCL-2 inhibitor, has improved response rates, and the addition of targeted compounds is currently explored. Maintenance therapies are increasingly applied to patients after allogeneic hematopoietic stem cell transplantation. Researchers are exploring options for CAR-T cell therapies for AML, and clinical studies exploring the potential of the anti-CD47 blockade in AML patients are on their way. These and closely related approaches are the focus of this Special Issue of Current Oncology.

Prof. Dr. Vera Ulrike Bacher
Prof. Dr. Thomas Pabst
Dr. Georg Stüssi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • acute myeloid leukemia (AML)
  • diagnostics
  • targeted therapies
  • immunotherapy
  • maintenance therapy

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1926 KiB  
Article
Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis
by Kimberly Guinan, Karine Mathurin, Yunghan Au, Andre C. Schuh, Cat N. Bui, Xinglei Chai and Jean Lachaine
Curr. Oncol. 2022, 29(10), 7524-7536; https://doi.org/10.3390/curroncol29100592 - 08 Oct 2022
Cited by 1 | Viewed by 2302
Abstract
Treatment for acute myeloid leukemia (AML) typically involves intensive chemotherapy (IC); however, there is an unmet need for approximately 50% of AML patients who are deemed unfit or ineligible for IC. The purpose of this study was to evaluate, from a Canadian perspective, [...] Read more.
Treatment for acute myeloid leukemia (AML) typically involves intensive chemotherapy (IC); however, there is an unmet need for approximately 50% of AML patients who are deemed unfit or ineligible for IC. The purpose of this study was to evaluate, from a Canadian perspective, the economic impact of venetoclax in combination with azacitidine (Ven+Aza) for the treatment of patients with newly diagnosed AML who are 75 years or older or who have comorbidities that preclude using IC. A lifetime partitioned survival model was developed to assess the cost-effectiveness of Ven+Aza compared with Aza. Health states included event-free survival, progressive/relapsed disease, and death. Efficacy parameters were based on the VIALE-A trial. Analyses were conducted from Ministry of Health (MoH) and societal perspectives. Over a lifetime horizon, Ven+Aza was associated with a gain of 1.65 quality-adjusted life years (QALYs) compared with Aza. From an MoH perspective, Ven+Aza and Aza were associated with total costs of $204,305 and $82,333, respectively, resulting in an incremental cost–utility ratio of $73,841/QALY. Results were similar from a societal perspective. This economic evaluation demonstrates that, in comparison with Aza, Ven+Aza is a cost-effective strategy for the treatment of patients with newly diagnosed AML who are deemed unfit for IC. Full article
(This article belongs to the Special Issue Future Perspectives for Diagnosis and Treatment of Acute Myeloid Leukemia (AML))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop